Company Profile

Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 16:00:00 2024-09-18 EDT			5-day change	1st Jan Change
0.5746 ^USD	-30.69%		-25.61%	-84.17%

25-07-01	Kineta, Inc. Announces Board Changes	CI
25-05-15	Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

25-07-01	Kineta, Inc. Announces Board Changes	CI
25-05-15	Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-28	Tuhura Biosciences and Kineta Present Updated Results from Kineta's Phase I-Ii Study of Kva12123 and Tuhura's Mechanism of Ifx-Hu2.0 Responses After Anti-Pd-1 Therapy Failure in Advanced Melanoma At the American Association for Cancer Research Annual Meeting	CI
25-03-06	Kineta, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-05	Kineta, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-02-09	An undisclosed buyer signed an asset purchase agreement to acquire specific intellectual property and related assets of Kineta, Inc for $1.	CI
24-11-24	TuHURA Biosciences, Inc. entered into a non-binding agreement to acquire Kineta, Inc. from Craig Philips and others for $30 million.	CI
24-11-08	Kineta, Inc. Updates KVA12123 Clinical Results from Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer	CI
24-11-06	Kineta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-10-08	Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors	CI
24-10-02	Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123	CI
24-09-23	Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index	CI
24-03-20	Kineta, Inc. Auditor Raises 'Going Concern' Doubt	CI

25-04-02	TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update	AQ
24-12-12	Kineta : TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.	PU
24-11-25	TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update Form 8 K	PU
24-11-08	Kineta : Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer Form 8 K	PU
24-11-08	Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)	AQ

1 week	-25.61%
1 month	+1.88%
3 months	+15.04%
6 months	+3.20%
Current year	-84.17%

Kineta, Inc. Stock Nasdaq

Stocks

KANT

US49461C1027

Biotechnology & Medical Research

Latest news : Kineta, Inc.

Press Releases: Kineta, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Kineta, Inc.

Bio Therapeutic Drugs

Company Profile

Income Statement and Estimates

1 week	0.56	0.89
1 month	0.56	0.89
3 years	0.33	78.35
5 years	0.33	660.8

Manager	Title	Age	Since
James Bianco PSD	President	69	2025-06-29
Tu Lee AUD	Comptroller/Controller/Auditor	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KINETA, INC.	-30.69%	-25.61%	-74.00%	-99.26%	4.55M
ARGENX SE	+0.68%	+5.92%	+77.86%	+139.22%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.26%	+91.40%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+43.36%	-4.67%	19.69B
GENMAB A/S	-0.29%	+9.78%	+43.90%	-28.41%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+186.15%	+361.42%	16.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+37.85%	-	14.84B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
Average	+2.87%	+8.57%	+41.42%	+119.99%	27.28B
Weighted average by Cap.	+2.46%	+6.47%	+58.32%	+136.97%